KZR stock forecast
Our latest prediction for Kezar Life Sciences, Inc.'s stock price was made on the Feb. 4, 2020 when the stock price was at 3.04$.
In the short term (2weeks), KZR's stock price should outperform the market by 2.68%. During that period the price should oscillate between -10.22% and +15.86%.
In the medium term (3months), KZR's stock price should outperform the market by 1.90%. During that period the price should oscillate between -39.01% and +43.07%.Get email alerts
About Kezar Life Sciences, Inc.
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco, California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.22$ per share.
The book value per share is 6.25$
Three months stock forecastFeb. 4, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|